Background {#Sec1}
==========

Sortases are membrane-bound cysteine transpeptidases that anchor surface proteins to the peptidoglycan cell wall in Gram-positive bacteria. Surface proteins anchored via sortases are often essential virulence factors important in colonization and invasion, evasion of the host immune system, and nutrient acquisition. The sorting process is mediated by a conserved C-terminal cell wall sorting signal on the anchored protein, comprised of a C-terminal recognition sequence (often LPXTG, where X is any amino acid), followed closely by a hydrophobic transmembrane domain and a positively charged tail \[[@CR1]\]. A conserved catalytic cysteine residue of the sortase cleaves the LPXTG motif of the polypeptide between the threonine and glycine residues and covalently attaches the protein to the peptidoglycan \[[@CR2]--[@CR6]\].

There are six described sortase families, A-F, that share amino acid similarity \[[@CR7]\]. All catalyze similar transpeptidation reactions, but recognize different substrate motifs and serve different functions within the cell. Class A sortases (SrtA), such as the prototypical *Staphylococcus aureus* Sortase A (SaSrtA), are considered housekeeping sortases as they are capable of anchoring many functionally distinct proteins to the cell wall. SaSrtA, which recognizes an LPXTG motif, is responsible for anchoring a variety of surface proteins involved in adherence and immune response evasion, and is essential for virulence in animal models \[[@CR8],[@CR9]\]. SrtA orthologues have been found in the genomes of almost all Gram-positive bacteria \[[@CR8],[@CR10]--[@CR16]\]. Class B sortases are functionally different from class A in their substrate specificity. In *S. aureus* and *B. anthracis*, the sortase B gene (*srtB*) is part of an iron-regulated locus *isd* (**i**ron-responsive **s**urface **d**eterminant) responsible for heme-iron transport, and anchors the iron transporter protein, IsdC, by recognizing an NPQTN motif \[[@CR17],[@CR18]\]. Though mutating *srtB* has no effect on establishing infection, SaSrtB is required for persistence of the bacterium in mice \[[@CR17]\].

*Clostridium difficile*, an anaerobic Gram-positive, spore-forming bacillus, is the leading cause of hospital-acquired infectious diarrhea in North America and Europe. Infection with *C. difficile* can result in a range of clinical presentations, from mild self-limiting diarrhea to the life-threatening pseudomembranous colitis (PMC), known collectively as *C. difficile* infection (CDI) \[[@CR19]\]. MLST studies have identified that the *C. difficile* population structure forms at least five distinct lineages that are all associated with CDI \[[@CR20]--[@CR22]\]. Complications of severe CDI can lead to toxic megacolon, bowel perforation, sepsis and death in up to 25% of cases \[[@CR23]\]. Broad-spectrum antibiotic usage is the greatest risk factor for development of CDI due to the consequent disruption of the intestinal microflora. Treatment of CDI with metronidazole and vancomycin can exacerbate the problem by continuing to disrupt the intestinal microflora. This leaves the patient susceptible to relapse or re-infection. Approximately one third of patients experience CDI relapse following treatment, and those who relapse have a greater risk of succumbing to the infection \[[@CR23]\]. A current imperative is the development of therapies that selectively target *C. difficile*, whilst leaving the intestinal microflora intact.

The *C. difficile* reference strain 630 encodes a single predicted sortase, CD630_27180, which has high amino-acid similarity with SrtB of *S. aureus* and *B. anthracis* \[[@CR24]\]. A second sortase encoded within the genome is interrupted by a stop codon prior to the catalytic cysteine and is considered a pseudogene. Thus, in contrast to other Gram-positive bacteria, *C. difficile* appears to have only a single functional sortase. As such, a compound that inhibits the activity of *C. difficile* sortase could target the pathogen without disrupting the numerous Gram-negative bacteria that make up the intestinal flora.

In this study, we demonstrate that the predicted sortase encoded by CD630_27180 recognizes and cleaves an (S/P)PXTG motif between the threonine and glycine residues. The cleavage of this motif is dependent on the conserved cysteine residue at position 209 in the predicted active site of the sortase. We have also identified seven putative sortase substrates, all of which contain the (S/P)PXTG motif. These substrates are conserved among the five *C. difficile* lineages and include potential adhesins, a 5' nucleotidase, and cell wall hydrolases. Furthermore, we identified a number of small-molecule inhibitors by means of an *in silico* screen that inhibit the activity of the *C. difficile* SrtB.

Results {#Sec2}
=======

Conservation of the catalytically active residues of sortase {#Sec3}
------------------------------------------------------------

The genome sequence of *C. difficile* strain 630 previously indicated the presence of a single copy of a sortase-like protein, encoded by *CD630_27180*, based on the presence of the sortase catalytic motif TLXTC \[[@CR24]\]. We performed BLAST searches (BlastP) to reveal the protein encoded by *CD630_27180* shares 32% and 34% amino acid identity with SrtB from *S. aureus* (SaSrtB) and *B. anthracis* (BaSrtB), respectively. In addition to the TLXTC active site, the catalytically essential histidine (His120 in SaSrtA) and arginine (R197 in SaSrtA) residues \[[@CR3],[@CR25],[@CR26]\] are conserved in the *C. difficile* SrtB. A structural prediction analysis of SrtB was performed using Phyre2 Protein Fold Recognition Server (<http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index>) \[[@CR27]\], and the resulting alignment suggests a high level of conservation between the predicted secondary structure of SrtB and the known crystal structure of the BaSrtB \[[@CR28]\] (Figure [1](#Fig1){ref-type="fig"}). Expression of *C. difficile* SrtB was analysed *in vitro* using RT-PCR analysis on strain 630, which confirmed that *CD2718* is actively transcribed during early exponential, late exponential and stationary phases (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Figure 1**Predicted** ***C. difficile*** **SrtB secondary structure** ***.*** A structural alignment between the known crystal structure of BaSrtB \[[@CR28]\] and the predicted structure of *C. difficile* SrtB using the Phyre2 Protein Fold Recognition Server suggests a high degree of structural conservation. Top: *C. difficile* SrtB predicted secondary structure and sequence. Bottom: BaSrtB sequence and known structure. Arrows indicate beta sheets, and striped rectangles indicate alpha helixes. Amino acid positions relative to start position are indicated. The sortase active site signature sequence TLXTC is boxed, as are the conserved essential histidine and arginine residues.

The *C. difficile* population structure forms at least five distinct clonal lineages that are all associated with human infection \[[@CR20]--[@CR22]\]. To determine whether SrtB is conserved between *C. difficile* strains, representatives for each of the five distinct clades were chosen for analysis based on the availability of a fully annotated sequence: *C. difficile* strains 630 for Clade 1, R20291 and CD196 (RT027) for Clade 2 \[[@CR29]\], M68 and CF5 (RT017) for Clade 3 \[[@CR20]\], CD305 (RT023) for Clade 4 (unpublished, WTSI), and M120 (RT078) for Clade 5 \[[@CR20]\]. BLAST searches of these representative strains show that *srtB* is conserved across all five *C. difficile* lineages. A second sortase-like gene in the 630 genome, classified as a pseudogene because of an in frame stop codon prior to the catalytic cysteine, is absent from the other four *C. difficile* lineages.

Bioinformatic prediction of sortase substrates {#Sec4}
----------------------------------------------

A bioinformatics approach was used for the preliminary identification of sortase substrate proteins in *C. difficile* strain 630. The predicted recognition sequence for CD630_27180 has been proposed to be (S/P)PXTG by Pallen *et al.* \[[@CR11]\], and recently to also include the sequence NVQTG, found in the surface- associated collagen binding protein CbpA, by Tulli *et al.* \[[@CR30]\]. Putative proteins were screened for the patterns (S/P)PXTG and NVQTG at the C-terminus \[[@CR11],[@CR30]\]. Putative candidates were then assessed for the known features of a sortase substrate: a predicted N-terminal signal peptide sequence, and a cell wall sorting signal comprising of a potential transmembrane domain following the sortase recognition sequence, and at least two consecutive basic residues (arginine or lysine) at the C-terminus \[[@CR31]--[@CR33]\].

Eight proteins satisfied our definition of a sortase substrate in strain 630 (Table [1](#Tab1){ref-type="table"}). The newly described *C. difficile* collagen binding protein A, CbpA, is the only protein containing the proposed NVQTG motif \[[@CR30]\]. The remaining proteins contained one of four observed variations of the (S/P)PXTG motif: SPKTG, PPKTG, and SPSTG and SPQTG. These predicted *C. difficile* sortase substrates are a diverse range of surface proteins that include putative cell wall hydrolases, putative adhesins, a collagen-binding protein, and a 5' nucleotidase/phosphoesterase (Table [1](#Tab1){ref-type="table"}). Transcriptional analysis performed by RT-PCR confirmed that all eight predicted substrate proteins are transcribed during growth *in vitro* (Additional file [1](#MOESM1){ref-type="media"}: Figure S1B-I). The eight predicted substrates are transcribed during all three growth phases examined, with the exception of CD630_25370 and CD630_32460, which do not appear to be transcribed during stationary phase. Four of these putative substrates are conserved across all five *C. difficile* lineages: CD630_01830, CD630_25370, CD630_27680, and CD630_28310.Table 1**Identification of putative** ***C. difficile*** **SrtB substrates in strain 630ProteinFunctionC-terminal sorting signal**CD630_01830Putative cell wall hydrolaseMIH**SPSTG**KT***V***S***V***TS***I***NSS***YY***TAR***FV***T***A*** *KR*ILCD630_03860Putative cell surface protein, collagen binding proteinPSD**SPKTG**DNTN***LY***G***LLALLL***TSG***A***G***LA***G***IFFY*** *KRRK*M*KK*SCD630_25370Putative membrane-associated 5\'-nucleotidase/phosphoesteraseKEK**SPKTG**D***L***G***F***SNS***IIIFIV***SST***LI***C***LL***N***F***NQ*K*EL*K*D*KK*S*K*CD630_27680Putative cell-wall hydrolaseFIH**SPQTG**D***VV***K***V***TS***MA***PGTN***YA*** *RR*LITAT*R*VLQCD630_28310Putative adhesion, collagen binding proteinPPV**PPKTG**DSTT***II***GE***ILLVI***G***AIV***G***LIVL*** *RR*N*K*NTNCD630_31450Collagen binding protein, CbpAVGQ**NVQTG**DQSN***IML***D***LALMFI***S***LFFLI*** *K*NLTN*K*YL*RRK*CD630_32460Putative surface proteinIVK**SPKTG**DETQ***LM***S***YVFI***S***VIAI***CG***LAY***QC*K*I*KR*NCD630_33920Putative cell surface protein, collagen binding proteinPSD**SPKTG**DSTN***LMAFIVMLLV***SGGG***LA***GT***YLY*** *KRRK*M*KK*SBold = predicted sortase recognition sequence.Bold and Italic = hydrophobic residues.Italics only = positively charged residues.

Purified *C. difficile* SrtB cleaves (S/P)PXTG peptides {#Sec5}
-------------------------------------------------------

To determine whether *C. difficile* SrtB cleaves putative substrates at the predicted motifs, FRET peptides were designed based on the variations observed in the predicted (S/P)PXTG motif (Table [2](#Tab2){ref-type="table"}). Two residues upstream of the motif were included, and two glycine residues were incorporated downstream, as this has been previously shown to improve sortase cleavage efficiency *in vitro* \[[@CR34]\]. Fluorescence of the Edans fluorophore within the peptides is blocked when in close proximity to the fluorescent quencher Dabcyl \[[@CR35]\]. When the peptide is cleaved, the Edans fluorophore is separated from Dabcyl, and a fluorescent signal is observed.Table 2**FRET peptide detailsPeptide sequence\*Description***d-*IHSPSTGGG*-e*Based on CD0183 sequence*d-*IHGSSTPGG*-e*Control for above peptide*d-*SDSPKTGGG*-e*Based on CD0386, CD3392 sequence*d-*SDGSKTPGG*-e*Control for above peptide*d-*IHSPQTGGG*-e*Based on CD2768 sequence*d-*IHGSQTPGG*-e*Control for above peptide*d-*PVPPKTGGG*-e*Based on CD2831 sequence*d-*PVGPKTPGG*-e*Control for above peptide*d-*GQNVQTGGG*-e*Based on CbpA sequence*d-*QALPETGGG*-e*SaSrtA peptide*d-*NPQTN*-e*SaSrtB peptide*d-*IHSPSTGKT*-e*Based on CD0183 sequence*d-*SDSPKTGDN*-e*Based on CD0386 sequence*d-*IHSPQTGDV*-e*Based on CD2768 sequence*d-*PVPPKTGDS*-e*Based on CD2831 sequence\*Where *d* is Dabcyl (4-(\[4-(dimethylamino)phenyl\]azo)-benzoyl) and *e* is Edans (5-((2-Aminoethyl)amino)naphthalene-1-sulfonic acid).

The N-terminal transmembrane domain of *C. difficile* SrtB (residues 2--25) was replaced with a six-histidine tag (SrtB~ΔN26~) to improve soluble protein yield. SrtB~ΔN26~ was expressed in *E. coli* NiCo21(DE3) and purified by nickel affinity chromatography from cleared lysates (Figure [2](#Fig2){ref-type="fig"}). Purified SrtB~ΔN26~ was then incubated with a FRET peptide containing the SPKTG sequence. An increase in fluorescence was observed over time, indicating that cleavage of the SPKTG peptide occurred in the presence of SrtB~ΔN26~ over 48 hours (Figure [3](#Fig3){ref-type="fig"}). In addition to the SPKTG motif, SrtB~ΔN26~ also cleaved peptides containing the predicted substrate sequences PPKTG, SPSTG, and SPQTG (Figure [4](#Fig4){ref-type="fig"}). SrtB~ΔN26~ failed to cleave the scrambled peptide sequences GSKTP, GPKTP, GSSTP and GSQTP (Figure [4](#Fig4){ref-type="fig"}). Interestingly, SrtB~ΔN26~ failed to cleave peptides containing the LPETG and NPQTN motifs of SaSrtA and SaSrtB, respectively, and also failed to cleave the proposed sortase recognition motif NVQTG found in the *C. difficile* collagen binding protein, CbpA \[[@CR30]\] (Figure [4](#Fig4){ref-type="fig"}).Figure 2**Expression and purification of SrtB** ~Δ**N26**~ **.** *E. coli* NiCo21(DE3) expressing SrtB~ΔN26~, in which the N-terminal membrane anchor has been replaced with a six-histidine tag, were lysed by sonication and cleared lysates purified by nickel affinity chromatography. **A**. Anti-his western testing for expression of SrtB~ΔN26~. Lane M: molecular mass marker, N: whole cell lysate of non-induced culture, I: whole cell lysate of culture induced with 1 mM IPTG. **B**. Coomassie-stained SDS-PAGE analysis of SrtB~ΔN26~ purification over an imidazole gradient. Lane L: molecular mass marker, W: column wash, imidazole gradient indicated by grey triangle, arrows indicate the SrtB~ΔN26~ protein~.~Figure 3**Cleavage of SPKTG peptide by recombinant SrtB** ~Δ**N26**~ **.** Purified recombinant SrtB~ΔN26~ was incubated with a FRET peptide containing the SPKTG motif and fluorescence measured every hour for the first eight hours, and also at 24 h, 36 h, and 48 h. An increase in relative fluorescence units (arbitrary units) was observed, compared with the peptide incubated alone, indicating that SrtB~ΔN26~ mediated cleavage of the SPKTG peptide occurred over a period of 48 hours. Error bars represent the standard error of the mean.Figure 4**SrtB** ~Δ**N26**~ **substrate specificity.** Purified recombinant SrtB~ΔN26~ protein was incubated with a range of peptide sequences to investigate its substrate specificity. The motifs SPKTG, PPKTG, SPSTG and SPQTG were all recognized and cleaved following incubation with SrtB~ΔN26~. The scrambled peptide sequences GSKTP, GPKTG, GSSTP, and GSQTP serve as controls for the cleavage specificity of SrtB~ΔN26~. The sequences LPETG and NPQTN, corresponding to the motifs recognized by *S. aureus* sortase A and B, respectively, do not appear to be substrates for SrtB~ΔN26~. SrtB~ΔN26~ also failed to cleave the proposed sorting signal NVQTG from recently characterized collagen binding protein, CbpA. Bars indicate the mean, and error bars represent the standard error (\*\*corresponds to *p* \< 0.01).

Analysis of FRET reaction {#Sec6}
-------------------------

To investigate the importance of the cysteine residue in the proposed active site of *C. difficile* SrtB, site-directed mutagenesis was used to replace the cysteine residue at position 209 with an alanine. When the resulting mutant protein SrtB~ΔN26,C209A~ was incubated with the FRET peptides, the fluorescent signal fell below the limits of detection (Figure [5](#Fig5){ref-type="fig"}), indicating that the cysteine residue at position 209 was essential for the activity of the *C. difficile* SrtB. Cleavage in the FRET-based assay was also inhibited by the addition of MTSET (Figure [5](#Fig5){ref-type="fig"}), a known cysteine protease inhibitor and inhibitor of sortase function in *S. aureus* \[[@CR36],[@CR37]\] and *B. anthracis* \[[@CR15]\].Figure 5**SrtB** ~Δ**N26**~ **activity requires a cysteine residue at position 209.** To determine if SrtB~ΔN26~ activity depended on the cysteine residue at position 209, a C209A substitution was made to create SrtB~ΔN26,C209A~. This enzyme was inactive against the FRET peptides when compared with SrtB~ΔN26~. Addition at 5 mM of the cysteine protease inhibitor, MTSET, to the reaction also eliminates activity (\*\*corresponds to *p* \< 0.01).

The cleavage of the SPKTG, PPKTG, and SPQTG motifs was enhanced at least two-fold by the addition of the two native amino acids immediately downstream of this sequon (data not shown). Analysis of the FRET reaction with these modified peptides revealed that SrtB~ΔN26,~ cleaves these peptides between the T and G residues. MALDI analysis of *d*-PVPPKTGDS-*e* peptide incubated with SrtB~ΔN26~ results in a peptide with a mass of 889 Da, corresponding to the fragment *d*-PVPPKT-OH (Figure [6](#Fig6){ref-type="fig"}, top). The peptide control, incubated without SrtB~ΔN26,~ lacked this fragment (Figure [6](#Fig6){ref-type="fig"}, bottom). Cleavage between the T and G residues for the *d*-SDSPKTGDN-*e* and *d*-IHSPQTGDV-*e* peptides was also confirmed (data not shown), indicating that *C. difficile* SrtB cleaves the (S/P)PXTG motif between the same residues as other functional sortases \[[@CR4],[@CR15],[@CR38],[@CR39]\].Figure 6**SrtB** ~Δ**N26**~ **cleaves FRET peptides between T and G residues.** MALDI analysis of FRET reaction products revealed a fragment of mass 889.46, corresponding to the predicted mass of *d-*PVPPKT-OH (top) when *d-*PVPPKTGDS-*e* was incubated with SrtB~ΔN26~. This fragment was absent in the mock treated peptide sample (bottom), indicating that SrtB~ΔN26~ cleaves the *d-*PVPPKTGDS*-e* between the T and G residues.

Kinetic measurements of SrtB activity {#Sec7}
-------------------------------------

In order to calculate the *in vitro* kinetic parameters of SrtB~ΔN26~ for the *d*-SDSPKTGDN-*e* and *d*-PVPPKTGDS-*e* peptides, we performed a kinetic analysis of the sortase-catalyzed hydrolysis reaction. Figure [7](#Fig7){ref-type="fig"}A shows the progress curves of the SrtB~ΔN26~ catalyzed hydrolysis reactions at various *d-*SDSPKTGDN*-e* concentrations. For each progress curve, the amount of fluorescent product (after conversion from RFU to concentration) was approximately 5% of the initial substrate concentration. Within the time period analyzed, the progress curves are linear, so the steady state rate (*V*) was determined by fitting the data to a linear function. Figure [7](#Fig7){ref-type="fig"}B shows *V* plotted against the concentration of the peptide. Non-linear regression of these data fitted to a modified Michaelis-Menten equation incorporating substrate inhibition (Equation [1](#Equ1){ref-type=""}):Figure 7**Kinetic parameters of SrtB** ~Δ**N26**~ **.** In order to determine the *in vitro* kinetic parameters of SrtB~ΔN26~ for the SPKTG and PPKTG motifs, we performed a kinetic analysis of the sortase-catalyzed hydrolysis reaction. **A**. Progress curves of the SrtB~ΔN26~-catalyzed hydrolysis reactions at various concentrations of *d-*SDSPKTGDN*-e* \[8 (blue ●), 10 (green ▪), 20 (red ▲), 40 (teal ▼), 80 (purple ♦), 160 (yellow ![](12866_2014_219_Figa_HTML.gif){#d30e1700}), 200 (black ★), and 240 μM (blue **+**). The steady state rate (*V*) was determined by fitting the data to a linear function. **B**. Plot of *V* against the concentration of the peptide \[*S*\]. Nonlinear regression of these data fitted to Equation [1](#Equ1){ref-type=""} resulted in a *K* ~*m*~ of 74.7 ± 48.2 μM for *d-*SDSPKTGDN*-e*. SrtB~ΔN26~ is subject to substrate inhibition at peptide concentrations \> 30 μM, which is not expected to be physiologically relevant.$$\documentclass[12pt]{minimal}
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Using SciPy 0.11.0 in Python 2.7.3, where *V*~*max*~ is the apparent maximal enzymatic velocity, *K*~*m*~ is the apparent Michaelis constant, and *K*~*i*~ is the apparent inhibitor dissociation constant for unproductive substrate binding. This resulted in a *K*~*m*~ of 74.7 ± 48.2 μM and a *K*~*cat*~ of 1.1×10^−3^ ± 6×10^−4^ min^−1^ for *d-*SDSPKTGDN*-e* (Figure [7](#Fig7){ref-type="fig"}B). This analysis was performed for *d-*PVPPKTGDS*-e*, resulting in a *K*~*m*~ of 53.3 ± 25.6 μM and a *K*~*cat*~ of 8.3×10^−4^ ± 3×10^−4^ min^−1^. SrtB~ΔN26~ is subject to substrate inhibition; at peptide concentrations greater than 30 μM, the rate of SrtB~ΔN26~ activity decreases. Substrate inhibition has previously been observed for other sortase enzymes *in vitro*, and is not expected to be physiologically relevant \[[@CR40]\].

Inhibiting SrtB activity {#Sec8}
------------------------

We sought to determine whether *C. difficile* SrtB could be specifically targeted using small-molecule inhibitors. The published crystal structure of the *B. anthracis* SrtB (BaSrtB) \[[@CR28]\] was used as a template for the selection of potential *C. difficile* SrtB inhibitors. These orthologous proteins show 70% identity and 90% similarity at the active site, and their differences are confined to the periphery of the active site. The proprietary *LeadBuilder* virtual-screening method (Domainex Ltd) was used to interrogate the *PROTOCATS* database of potential protease inhibitors with pharmacophoric and docking filters derived from analysis of the BaSrtB crystal structure. *PROTOCATS* comprises 80,000 commercially-available compounds that may form reversible transition-state-like complexes with protease enzymes. Compounds in *PROTOCATS* contain a carbonyl group which is activated to make a fully reversible complex with the active-site serine/cysteine group by virtue of adjacent moderately electron-withdrawing substituents, which are not leaving groups. Some examples of these functional groups are α-ketoamides and aryl ketones. Figure [8](#Fig8){ref-type="fig"}A shows one of the identified compounds docking within the active site structure of BaSrtB.Figure 8**SrtB** ~Δ**N26**~ **activity can be inhibited by rationally designed inhibitors.** The proprietary *LeadBuilder* virtual-screening method (Domainex Ltd) was used to screen a database of 80,000 potential protease inhibitors, *PROTOCATS*, with pharmacophoric and docking filters derived from analysis of the BaSrtB crystal structure \[[@CR28]\]. **A**. Space filling model showing one of the hit compounds fitting into the active site of BaSrtB and interacting with the catalytic cysteine residue. **B**. MTSET and the hits from the virtual screen were tested in the FRET-based assay at varying concentrations to screen for inhibition of SrtB~ΔN26~ mediated cleavage of *d-*PVPPKTGDS*-e*. The most effective compounds were LSHTM40, LSHTM50, and LSHTM52, which had IC50 values of 63.1 ± 8.8, 60.1 ± 4.7 and 44.1 ± 6.9 μM, respectively. The IC50 for MTSET was 286.7 ± 16.6 μM, indicating its inhibitory effect on SrtB~ΔN26~ is less potent than the three identified compounds.

Compounds identified in this screen as potential SrtB inhibitors were tested alongside the cysteine protease inhibitor MTSET at a range of concentrations in the FRET-based assay using the *d*-PVPPKTGDS-*e* peptide to compare IC50 values. Addition of MTSET reduced SrtB~ΔN26~ activity to below the limits of detection at concentrations of 500 μM and greater. MTSET exhibited an IC50 of 286.7 ± 16.6 μM (Figure [8](#Fig8){ref-type="fig"}B). A panel of potential *C. difficile* SrtB inhibitors were screened for inhibition of SrtB~ΔN26~ activity. The most effective of the 62 compounds were LSHTM40, LSHTM50, and LSHTM52. They had IC50 values below 100 μM (Figure [8](#Fig8){ref-type="fig"}B, Table [3](#Tab3){ref-type="table"}), at 63.1 ± 8.8 μM, 60.1 ± 4.7 μM, and 44.1 ± 6.9 μM, respectively, showing a good efficacy against *C. difficile* SrtB activity.Table 3**Structure of most effective inhibitors of SrtB** ~Δ**N26**~**CompoundStructureIC50**LSHTM-0040![](12866_2014_219_Figb_HTML.gif){#d30e2043}63.1 ± 8.8 μMLSHTM-0050![](12866_2014_219_Figc_HTML.gif){#d30e2056}60.1 ± 4.7 μMLSHTM-0052![](12866_2014_219_Figd_HTML.gif){#d30e2069}44.1 ± 6.9 μM

Discussion {#Sec9}
==========

*C. difficile* infection is invariably associated with the disruption of the normal intestinal microflora by the administration of broad spectrum antibiotics. Thus there is a pressing need to develop therapies that selectively target *C. difficile* while leaving the intestinal microflora intact. The *C. difficile* reference strain 630 encodes a single predicted sortase, CD630_27180, which has strong amino acid similarity with SrtB of *S. aureus* and *B. anthracis* \[[@CR24]\]. Sortase substrates frequently contribute toward pathogenesis via their involvement in attachment to specific tissues during infection \[[@CR17],[@CR41]--[@CR44]\], as well as the bacteria's ability to evade the immune response of the host \[[@CR32],[@CR36]\]. Sortases, although not essential for growth or viability of the organism, are often essential for virulence in Gram-positive organisms; inactivation of sortases reduces colonization in mice \[[@CR8],[@CR13],[@CR44],[@CR45]\], and decreases adhesion and invasion *in vitro* \[[@CR8],[@CR10],[@CR14],[@CR46],[@CR47]\]. Sortases and their substrates are considered promising targets for the development of new anti-infective compounds \[[@CR10],[@CR14],[@CR48]\]. Unusually for Gram-positive bacteria, *C. difficile* appears to possess a single sortase enzyme that is likely to be important for the viability of the pathogen as we have been unable to construct a *C. difficile* strain 630 SrtB defined mutant (unpublished data). Inhibiting the *C. difficile* sortase could prove to be a strategy to specifically target *C. difficile*.

In this study, we cloned, expressed and characterized the sortase encoded by *CD630_27180* of *C. difficile* 630, a predicted class B sortase (SrtB). Sortase nomenclature is based on sequence similarity to the known classes of sortase, A-F \[[@CR7]\]. Sortases of class B typically are involved in heme-iron uptake and tend to be expressed in operons with their substrates \[[@CR17],[@CR18]\]. Genes encoding class A sortases are not found in proximity to their substrates, which consist of a variety of surface proteins with diverse biological functions. Several exceptions to these rules have already been described, notably a class B sortase that polymerizes pilin subunits in *S. pyogenes* \[[@CR49]\], and a class E sortase from *C. diphtheriae* that serves a housekeeping function \[[@CR50]\]. The potential *C. difficile* sortase substrates identified in this paper comprise a diverse range of surface proteins, suggesting that SrtB may serve as a housekeeping sortase in *C. difficile*, a function usually reserved for class A sortases.

These potential sortase substrates in *C. difficile* strain 630 comprise of seven proteins, all containing an (S/P)PXTG motif, that are predicted to be surface localized and are conserved across *C. difficile* strains. Recently it was proposed that a *C. difficile* collagen binding protein, CbpA, may be sorted to the cell surface by sortase recognizing an NVQTG motif \[[@CR30]\]. In this study, we developed a FRET-based assay to demonstrate that SrtB of *C. difficile* recognizes and cleaves the (S/P)PXTG motif between the threonine and glycine residues, and that cleavage is dependent on a single cysteine residue at position 209. SrtB~ΔN26~ does not appear to cleave the *S. aureus* SrtA and SrtB motifs, LPXTG and NPQTN, respectively, nor the NVQTG motif *in vitro*, suggesting that CbpA from *C. difficile* may be attached to the cell surface by another mechanism.

The FRET-based assay enabled us to determine kinetic parameters for the recombinant *C. difficile* SrtB. Although the catalytic activity appears low, low catalytic efficiency is observed for most sortases *in vitro* \[[@CR40],[@CR51]\]. The kinetic and cleavage data we report for SrtB~ΔN26~ is consistent with this trend. *In vivo*, the sorting motifs are part of a larger protein, and the transpeptidation substrates are part of a cell wall precursor or mature peptidoglycan \[[@CR5],[@CR6],[@CR39]\]. The transpeptidation reaction has been observed *in vitro* for sortases from bacteria with a Lys-type peptidoglycan, where cross-linking occurs through a peptide bridge \[[@CR52],[@CR53]\] such as *S. aureus* and *Streptococcus* species \[[@CR4],[@CR40],[@CR54]\], but not for bacteria with Dap-type peptidoglycan such as *Bacillus* with direct cross-linkages through *m*-diaminopimelic acid \[[@CR55]\]. The likely cell wall anchor of the *C. difficile* SrtB substrates is the diaminopimelic acid cross-link \[[@CR56]\], similar to *Bacillus*. When transpeptidation is observed *in vitro*, the cleavage efficiency of sortase increases.

This study revealed that recombinant SrtB~ΔN26~ cleaves the (S/P)PXTG motifs with varying levels of efficiency, cleaving the sequences PPKTG and SPQTG with the greatest efficiency. Apparent preferential cleavage efficiency of certain substrate sequences *in vitro* has been observed in other sortases. For example, in *B. anthracis*, BaSrtA cleaves LPXTG peptides more readily than a peptide containing the sequence LPNTA \[[@CR15]\]. The biological significance of this peptide sequence preference is unknown.

Small-molecule inhibitors with activity against SrtA and SrtB have been reported that prevent cleavage of fluorescently-labelled peptide compounds by sortase *in vitro* \[[@CR57]\]. These compounds inhibit cell adhesion to fibronectin, yet, they have no effect on *in vitro* growth. Inhibitors tested against SrtA, SrtB and SrtC in *B. anthracis* irreversibly modified the active cysteine residue \[[@CR58]\]. Several compounds identified in this study had an inhibitory effect on *C. difficile* SrtB activity. However, these lead compounds had no direct effect on *in vitro C. difficile* growth (data not shown), which is consistent with observations in *S. aureus* \[[@CR57]\]. Inhibition of bacterial growth is not considered vital in the development of sortase-based drug therapies. In both *Staphylococcus* and *Bacillus*, sortase inhibitors show good suitability for further development as therapeutics despite their lack of bactericidal activity. When mice challenged with *S. aureus* were treated with sortase inhibitor compounds, infection rates and mortality were reduced \[[@CR59]\], despite these compounds having no effect on staphylococcal growth \[[@CR57]\]. The use of *in silico* approaches such as the LeadBuilder method employed by this study to screen databases of putative small-molecule inhibitors for further analysis has been validated. Further analysis of the structural similarities between the hit compounds could lead to a refinement of SrtB inhibitor design and increased potency *in vitro*.

Conclusions {#Sec10}
===========

In conclusion, we demonstrate that *C. difficile* encodes a single sortase, SrtB, with *in vitro* activity. We have confirmed the *C. difficile* SrtB recognition sequence as (S/P)PXTG, and show that *C. difficile* SrtB cleaves the (S/P)PXTG motif within peptides between the threonine and glycine residues. The cysteine residue within the predicted active site is essential for activity of the enzyme, and the cleavage of fluorescently-labelled peptides can be inhibited by MTSET, a known cysteine protease inhibitor. SrtB inhibitors identified through our *in silico* screen show a greater level of efficacy then MTSET at inhibiting the protease activity of *C. difficile* SrtB. Such inhibitors provide a significant step in successfully identifying *C. difficile* SrtB inhibitor compounds, which can be further refined to enhance their efficacy, and may contribute towards the development of novel selective therapeutics against CDI.

Methods {#Sec11}
=======

Bacterial culture {#Sec12}
-----------------

*C. difficile* strain 630 \[[@CR24]\] was cultured on Brazier's agar (BioConnections) supplemented with 4% egg yolk (BioConnections) and 1% defibrinated horse blood (TCS Biosciences Ltd.). Liquid cultures were grown in brain heart infusion broth (Oxoid Ltd.) supplemented with 0.05% L-cysteine (BHIS broth). All media was supplemented with *C. difficile* antibiotic supplement (250 μg/ml D-cycloserine and 8 μg/ml cefoxitin, BioConnections). *C. difficile* cultures were incubated at 37°C for 24--48 hours in a Whitley MG500 anaerobic workstation (Don Whitley Scientific Ltd.).

One Shot Top10® (Invitrogen) and XL-1 Blue (Agilent) *Escherichia coli* were used for all cloning steps, and NiCo21(DE3) *E. coli* (NEB) was used for the expression of recombinant proteins \[[@CR60]\]. *E. coli* strains were grown at 37°C on Luria-Bertani (LB) agar (Novagen) or in LB broth (Difco). Media was supplemented with 100 μg/ml ampicillin or 50 μg/ml kanamycin as required.

Genomic DNA isolation {#Sec13}
---------------------

Genomic DNA was isolated from *C. difficile* strain 630 \[[@CR24],[@CR61]\] by phenol chloroform extraction as previously described \[[@CR29]\] and used as a template for cloning. The annotated genome sequences from *C. difficile* strains R20291 and CD196 (RT027) \[[@CR29]\], M68 and CF5 (RT017) \[[@CR20]\], M120 (RT078) \[[@CR20]\], and CD305 (RT023) (unpublished, Wellcome Trust Sanger Institute) were used for analysis.

Identification of sortase substrates {#Sec14}
------------------------------------

All proteins encoded by *C. difficile* strain 630 \[[@CR24],[@CR61]\] were searched for the patterns (S/P)PXTG \[[@CR11]\] and NVQTG \[[@CR30]\] positioned 17--45 amino acid residues from the C-terminus \[[@CR31]\]. The resulting candidate protein list was assessed for the known features of a sortase substrate: (i) a suitable N-terminal signal peptide sequence, as predicted by SignalP 4.1 Server (<http://www.cbs.dtu.dk/services/SignalP/>) \[[@CR62]\], (ii) a potential transmembrane segment following the C-terminal "LPXTG-like" sequence, as predicted by TMHMM Server v. 2.0 (<http://www.cbs.dtu.dk/services/TMHMM/>) \[[@CR63]\], and (iii) at least two consecutive basic residues (arginine or lysine) at the C-terminus \[[@CR31]--[@CR33]\].

Genetic manipulation {#Sec15}
--------------------

A list of primers and plasmids used in this study can be found in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}, respectively. The coding sequence for *srtB* (CD630_27180) was codon-optimized for expression in *E. coli* by Celtek Bioscience, LLC (Nashville, TN, USA). The resulting fragment was cloned into the NcoI/XhoI sites of pET28a using primers pET_3 and pET_4 to create pET28a-*srtB*. To improve soluble SrtB yield, the N-terminal transmembrane anchor domain (residues 2--25) was replaced with a six-histidine tag. The truncated gene *srtB*~ΔN26~ was amplified from pET28a-*srtB* using primers pET_17 and pET_16, and cloned into the NcoI/XhoI sites of pET28a to create pET28a-*srtB*~ΔN26~. The mutant protein SrtB~ΔN26,C209A~ was generated using the QuikChange Site-Directed Mutagenesis kit (Agilent) in accordance with the manufacturer's instructions using pET28a-*srtB*~ΔN26~ as a template and primers C209A and C209A_antisense. Successful construction of recombinant plasmids was confirmed by DNA sequencing using primers T7F and T7R (Source BioScience).Table 4**Primers used in this studyPrimerSequence**pET_3gatattccatggatgaagaaactgtaccgtatcgttatcpET_4gatgagctcgaggatcagacgaccgtggataaccpET_17gatataccatggatgcaccaccaccaccaccactctaaactgaccaaatacaaccacgacacpET_16gatgagctcgagttagatcagacgaccgtggataacC209AtcgttaccctgtctaccgccacctacgaattcgacgC209A_antisensecgtcgaattcgtaggtggcggtagacagggtaacgaT7FtaatacgactcactatagggT7RgctagttattgctcagcggTable 5**Plasmids used in this studyPlasmidDescriptionReference**pQE30Xa- *srtB*Codon optimized *srtB*, synthesized and cloned in pQE30xaObtained from Celtek Bioscience, LLCpET28aCommercial protein expression vectorProvided by Neil FairweatherpET28a- *srtB*Codon optimized *srtB* cloned in pET28aThis workpET28a- *srtB* ~ΔN26~*srtB* with residues 2--25 replaced with a six-histidine tagThis workpET28a- *srtB* ~ΔN26,C209A~Same as above, with C209A substitutionThis work

RT-PCR analysis {#Sec16}
---------------

Total RNA was isolated from *C. difficile* 630 grown in BHIS at early exponential phase (t = 3 hours, OD~600~ = 0.4-0.5), late exponential phase (t = 5 hours, OD~600~ = 0.8-0.9), and stationary phase (t = 24 hours, OD~600~ = 0.6-0.8) using RNAprotect Bacteria Reagent (Qiagen) and the FastRNA Pro Blue Kit (MP Biomedicals LLC., Illkirch, France) in accordance with the manufacturer's instructions. Genomic DNA was removed from total RNA samples using TURBO DNase (Life Technologies). Equal amounts of RNA were reverse transcribed into complementary DNA (cDNA) for expression analysis. Briefly, one μg random primers (Invitrogen) and 40 units RNasin Plus RNase inhibitor (Promega) was added to one μg RNA in a final volume of 10 μl, and incubated at 65°C for 10 min followed by room temperature for 30 min. The following first-strand mixture was added for cDNA synthesis: four μl of 5x first-strand buffer (Invitrogen), two μl 0.1 M DTT (Invitrogen), two μl 10 mM dNTP mix (New England BioLabs), and 1.5 μl Superscript II (Invitrogen). The reaction mixture was incubated at 25°C for 10 minutes, 42°C for 1 h, and finally 70°C for 15 minutes. RT-PCRs were performed with gene specific primers (Additional file [2](#MOESM2){ref-type="media"}: Table S1) using cDNA as a template.

Purification of recombinant protein {#Sec17}
-----------------------------------

Expression constructs were transformed into *E. coli* NiCo21(DE3) (NEB). Cultures grown at 37°C were induced for expression with 1 mM IPTG when the OD~600~ reached 0.6, and harvested after 5 hours. Cell pellets were resuspended in lysis buffer \[1× Bugbuster (Novagen), 50 mM NaH~2~PO~4,~ 300 mM NaCl, 40 mM imidazole, 1 mM DTT, 1 mg/ml lysozyme, and 25 U/ml Benzonase nuclease (Novagen) (pH 7.5)\]. Lysates were sonicated on ice for 2 min (15 sec on/off) at 50% Vibra Cell™ high intensity ultrasonic processor (Jencon, Leighton Buzzard, Bedfordshire, UK) before centrifugation at 10,000 rpm for 45 min. The supernatant was passed through a 0.22 μM filter before applying to a 1 ml HisTrap HP column (GE Healthcare), pre-equilibrated with buffer (50 mM NaH~2~PO~4,~ 300 mM NaCl, 40 mM imidazole, 1 mM DTT, pH 7.5). SrtB~ΔN26~ was eluted with an imidazole gradient (40 -- 500 mM) over 25 column volumes. Fractions containing SrtB~ΔN26~ (as identified by SDS-PAGE) were pooled and injected onto a HiLoad 16/60 Superdex 200 column (GE Healthcare) pre-equilibrated with buffer F (5 mM CaCl~2~, 50 mM Tris--HCl (pH 7.5), 150 mM NaCl, 1 mM DTT). Eluted fractions containing SrtB~ΔN26~ were pooled and concentrated using an Amicon Ultra-15 (10 kDa) centrifuge filter unit (Millipore). Protein samples were quantified using Bradford reagent (Thermo Scientific) and analyzed by SDS-PAGE. The mutant protein SrtB~ΔN26,C209A~ was expressed and purified following the above method. Expression of SrtB~ΔN26~ and SrtB~ΔN26,C209A~ was confirmed by MALDI fingerprinting.

Immunoblotting {#Sec18}
--------------

Samples were resolved on Novex NuPage 10% Bis-Tris SDS-PAGE gels (Invitrogen) before transferring to Hybond*-*C Extra nitrocellulose (GE Healthcare). Membranes were probed with rabbit antiserum directed against 6xHis-tag (1:5000, Abcam), followed by goat anti-rabbit IRDye conjugated secondary antibody (1:7500, LI-COR Biotechnology). Blots were visualized using an Odyssey near-infrared imager (LI-COR Biotechnology).

*In vitro* analysis of sortase activity {#Sec19}
---------------------------------------

SrtB~ΔN26~ activity was monitored using a fluorescence resonance energy transfer (FRET) assay \[[@CR58]\] in buffer F (5 mM CaCl~2~, 50 mM Tris--HCl (pH 7.5), 150 mM NaCl, and 1 mM DTT). Fluorescently self-quenched peptides tagged with 5-((2-Aminoethyl)amino)naphthalene-1-sulfonic acid (Edans) as a fluorophore and 4-(\[4-(Dimethylamino)phenyl\]­azo)­benzoic acid (Dabcyl) as a quencher \[[@CR35]\], and containing the predicted sorting signals of SrtB were purchased from Protein Peptide Research Ltd and solubilized in DMSO (Table [2](#Tab2){ref-type="table"}). The FRET-based assay was performed in a final volume of 100 μl buffer F containing 10 μM SrtB~ΔN26~ and 20 μM fluorogenic peptide in clear-bottomed, black polystyrene 384-well plates (Nunc). Plates were incubated for 48 hours at 37°C, during which fluorescence (excitation = 340 nm, emission = 490 nm) was measured using a SpectraMax M3 plate reader (Molecular Devices). Five mM 2-(trimethylamonium)ethylmethanethiosulfonate (MTSET, Affymetrix) was added to the reaction as indicated. Each experiment was performed in triplicate with a minimum of three biological replicates, and the results are presented as the means and the standard error of the data obtained. The two-tailed Student's T-test was used to analyze the data. MALDI analysis of FRET reaction samples was performed by the Protein and Nucleic Acid Chemistry Facility (University of Cambridge) to determine exact cleavage site within each peptide.

Kinetic measurements {#Sec20}
--------------------

Kinetic data for SrtB~ΔN26~ were obtained by incubating varying concentrations of peptide (8, 10, 20, 40, 80, 160, 200 and 240 μM) with 10 μM SrtB~ΔN26~. All reactions were performed as described above, with fluorescence monitored every ten minutes over a 13 hour period. To correlate fluorescence signal, expressed as arbitrary relative fluorescence units (RFU), with the concentration of product formed, standard curves of the fluorophore Edans were collected. The linear segment of the fluorophore standard curve generated a conversion ratio of 703.9 RFU/ μM Edans. Initial velocities (*V*) were determined from the progress curves and plotted against substrate concentration \[*S*\]. The data were fitted to a modified version of the Michaelis-Menten equation incorporating substrate inhibition using SciPy 0.11.0 in Python 2.7.3, where *V*~*max*~ is the maximal enzymatic velocity, *K*~*m*~ is the Michaelis constant, and *K*~*i*~ is the inhibitor dissociation constant for unproductive substrate binding. All data points were collected in triplicate, and the overall assay was run in duplicate.

Identification of SrtB inhibitors {#Sec21}
---------------------------------

The proprietary *LeadBuilder* virtual screening method (Domainex, Ltd) was used to interrogate a database (*PROTOCATS*) of 80,000 potential compounds which had been pre-selected as protease inhibitors. The virtual screening protocol used pharmacophoric and docking filters derived from analysis of the BaSrtB crystal structure (with which the *C. difficile* SrtB shows 70% identity and 90% similarity at the active site). Sixty-two compounds identified in this screen as potential SrtB inhibitors were obtained from Enamine, ChemBridge, and Key Organics, and solubilized in DMSO. Selected compounds and MTSET were incubated with 10 μM SrtB~ΔN26~ at a range of concentrations in the FRET-based assay conditions described above, so that final DMSO concentrations were ≤ 3.75%, a concentration shown to have no significant effect on control fluorescence (data not shown). IC50 values were determined by non-linear least squares fit to a four parameter sigmoidal function using SciPy 0.11.0 in Python 2.7.3.

Additional files {#Sec22}
================

Additional file 1: Figure S1.RT-PCR analysis in *C. difficile* strain 630 of *CD2718* and its predicted substrates. PCR reactions were performed with 630 cDNA that was prepared from cultures grown to early exponential (E), late exponential (L) and stationary phase (S). M = Hyperladder I (Bioline), G = 630 genomic DNA, W = dH~2~O. A "+"indicates cDNA reaction with added reverse transcriptase, "-" indicates cDNA reaction without added reverse transcriptase (control for DNA depletion of RNA sample).Additional file 2: Table S1.Primers used for RT-PCR analysis.
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